Multidrug-resistant tuberculosis in patients without HIV infection

Area of Science:

• Infectious Diseases
• Pulmonology
• Public Health

Background:

• Multidrug-resistant tuberculosis (MDR-TB) outbreaks typically involve patients with advanced HIV infection, showing poor treatment outcomes.
• Previous studies reported lower treatment response (56%) and higher mortality (22%) for MDR-TB in HIV-negative individuals.
• This study focuses on treatment response and mortality in HIV-negative patients with MDR-TB in New York City.

Purpose of the Study:

• To investigate treatment response and mortality rates in HIV-negative patients diagnosed with multidrug-resistant tuberculosis.
• To assess the efficacy of appropriate chemotherapy in this specific patient population.
• To compare findings with previous reports on MDR-TB outcomes.

Main Methods:

• Data collected from seven New York City teaching hospitals for HIV-negative patients with MDR-TB (resistant to isoniazid and rifampin).
• Assessed time from diagnosis to therapy initiation and time to culture conversion.
• Evaluated therapeutic response using both clinical and microbiologic criteria.

Main Results:

• Of 25 analyzed HIV-negative patients, 96% achieved clinical response, and 100% of 17 with available data showed microbiologic response.
• Median time to therapy initiation was 44 days; median time to culture conversion was 69 days.
• 17% of patients on second-line drugs experienced side effects requiring medication discontinuation.

Conclusions:

• HIV-negative patients with MDR-TB in New York City demonstrated favorable clinical and microbiologic responses to appropriate chemotherapy.
• Findings contradict previous reports suggesting poor outcomes for this patient group.
• Appropriate and timely treatment is crucial for improving MDR-TB outcomes in HIV-negative individuals.